Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for MDS patients: drug may end need for platelet transfusions

NCT ID NCT04797000

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called eltrombopag in adults with a low-risk form of myelodysplastic syndromes (MDS) who regularly need platelet transfusions. The goal is to see if the drug can help them go without transfusions for at least 8 weeks. About 36 people in Japan will take part, and half will get the drug while the other half gets a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

  • Novartis Investigative Site

    Narita, Chiba, 286-8523, Japan

  • Novartis Investigative Site

    Kurume, Fukuoka, 830-8543, Japan

  • Novartis Investigative Site

    Ohtake, Hiroshima, 739-0696, Japan

  • Novartis Investigative Site

    Nishinomiya, Hyōgo, 663 8501, Japan

  • Novartis Investigative Site

    Kanazawa, Ishikawa-ken, 920-8530, Japan

  • Novartis Investigative Site

    Isehara, Kanagawa, 259-1193, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, 221-0855, Japan

  • Novartis Investigative Site

    Sendai, Miyagi, 9808574, Japan

  • Novartis Investigative Site

    Nagasaki, Nagasaki, 852-8501, Japan

  • Novartis Investigative Site

    Sakai, Osaka, 590-0197, Japan

  • Novartis Investigative Site

    Bunkyo-ku, Tokyo, 113-8603, Japan

  • Novartis Investigative Site

    Itabashi Ku, Tokyo, 173 8606, Japan

  • Novartis Investigative Site

    Shimonoseki, Yamaguchi, 750-0061, Japan

  • Novartis Investigative Site

    Aomori, 030 8553, Japan

  • Novartis Investigative Site

    Chiba, 260-0852, Japan

  • Novartis Investigative Site

    Fukushima, 9601295, Japan

  • Novartis Investigative Site

    Gifu, 5008513, Japan

  • Novartis Investigative Site

    Kumamoto, 860-0008, Japan

  • Novartis Investigative Site

    Osaka, 5340021, Japan

  • Novartis Investigative Site

    Yamagata, 990 9585, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.